News Releases

September 5, 2019
Unum Therapeutics to Present at Upcoming Industry Conferences in September
CAMBRIDGE, Mass. , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced its participation in the following industry conferences in September: Cell & Gene Therapy
August 26, 2019
Unum Therapeutics to Present at Upcoming September Investor Conferences
CAMBRIDGE, Mass. , Aug. 26, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced that Charles Wilson , Ph.D., President and Chief Executive Officer, will present at two
August 12, 2019
Unum Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Updates
- Updated results from Phase 1 trial with ACTR707 in combination with rituximab in adults with relapsed/refractory non-Hodgkin lymphoma confirms the clinical activity achieved in previous cohorts with no adverse events of cytokine release syndrome or severe neurotoxicity –                     
August 2, 2019
Unum Therapeutics to Review Second Quarter 2019 Financial Results on August 12, 2019
CAMBRIDGE, Mass. , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing potentially curative cellular immunotherapies through its ACTR and BOXR platforms, today announced that the company will host a conference call and live
July 29, 2019
Unum Therapeutics Announces New Appointments to its Board of Directors
CAMBRIDGE, Mass. , July 29, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, ACTR and BOXR, today announced the
July 17, 2019
Unum Therapeutics to Present at the Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass. , July 17, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, today announced that Charles Wilson , Ph.D.,
July 2, 2019
Unum Therapeutics Announces Regulatory Update from Phase 1 Trial with ACTR087
CAMBRIDGE, Mass. , July 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, today announced that the U.S.
June 13, 2019
Unum Therapeutics Strengthens and Expands Leadership Team
– Matthew Osborne Appointed as Chief Financial Officer – – Jessica Sachs Promoted to Chief Medical Officer – – Mert Aktar Appointed as Head of Business and Corporate Development – CAMBRIDGE, Mass. , June 13, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc.
May 13, 2019
Unum Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
- Advancing ACTR Clinical Programs in Non-Hodgkin Lymphoma, Multiple Myeloma, and HER2+ Advanced Cancers Through Dose Escalation Studies with Data Expected from All Four Ongoing Trials in Second Half of 2019 - - Advancing and Expanding BOXR Pipeline Focused on Solid Tumor Cancers Through
May 6, 2019
Unum Therapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 13, 2019 at 8:00 A.M. ET
CAMBRIDGE, Mass. , May 06, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer using its novel T cell technology platforms, today announced that the company will host a
Displaying 1 - 10 of 17
The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.